BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

Sung-Bae KIM; In-Gu DO; Janice TSANG; Tae-You KIM; Yoon-Sim YAP; Gerardo CORNELIO; Gyungyub GONG; Soonmyung PAIK; Suee LEE; Ting-Ying NG; Sarah PARK; Ho-Suk OH; Joanne CHIU; Joohyuk SOHN; Moonhee LEE; Young-Jin CHOI; Eun-Mi LEE; Kyong-Hwa PARK; Christos NATHANIEL; Jungsil RO.
Cancer Research and Treatment ; : 1527-1539, 2019.
Artículo en Inglés | WPRIM | ID: wpr-763208

Documentos relacionados

  1. Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer.
  2. [Development in the last 20 years of anti-HER2 targeted therapy for breast cancer].
  3. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
  4. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
  5. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
  6. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan.
  7. Effect of aerobic exercise on cardiotoxic outcomes in women with breast cancer undergoing anthracycline or trastuzumab treatment: a systematic review and meta-analysis.
  8. Plasma hPG<sub>80</sub> (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort.
  9. Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.
  10. Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.